Table 1.

Safety and efficacy comparison between IFN-based therapy and IFN-free DAA therapy in special populations

Indicator/population	IFN-based therapy	IFN-free DAA therapy
SVR rate %
Hemodialysis	40–41% [21, 49]	90–100% [31, 32, 47, 58, 60, 75]
HIV/HCV co-infection	27–40% [79–81]	78–98% [35, 36, 84, 85, 87, 88, 90, 107]
Liver transplantation	8–50% [95]	70–98% [38, 39, 85, 99, 101–103, 105, 106]
Treatment discontinuation rate
Hemodialysis	14–16% [21, 49]	0–5% [31, 32, 47, 58, 60, 75]
HIV/HCV co-infection	12–39% [79–81]	0–3% [35, 36, 84, 85, 87, 88, 90, 107]
Liver transplantation	27.6% [95]	2–18% [38, 39, 85, 99, 101–103, 105, 106]

IFN interferon, DAA direct-acting antiviral, HIV human immunodeficiency virus, HCV hepatitis C virus